Optimisation of a potent and fast acting antimalarial class that is orally efficacious in vivo

优化一种有效且快速起效的抗疟药物，该药物在体内口服有效

• 批准号: nhmrc : 1135421
• 负责人: A/Pr Justin Boddey
• 金额: $ 46.24万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/optimisation-potent-fast-efficacious-vivo/1318234
• 关键词: Optimisation; potent; fast; acting; antimalarial

Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. We have identified a highly active antimalarial series that we propose to further develop to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.

疟疾是一种破坏性疾病，每年导致60万人死亡。由于耐药性的出现，目前用于防治疟疾的治疗药物在临床上的使用时间有限。我们已经确定了一个高度活跃的抗疟疾系列，我们建议进一步开发，以满足与疟疾药物合资企业(MMV)合作进入临床所需的先决条件。